Segall Bryant & Hamill LLC Buys 17,354 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Segall Bryant & Hamill LLC increased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 29.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 76,460 shares of the medical instruments supplier's stock after purchasing an additional 17,354 shares during the quarter. Segall Bryant & Hamill LLC owned 0.34% of LeMaitre Vascular worth $6,415,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in LeMaitre Vascular by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock worth $50,711,000 after purchasing an additional 7,737 shares during the period. Northern Trust Corp lifted its holdings in LeMaitre Vascular by 5.1% during the fourth quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock worth $30,205,000 after buying an additional 15,843 shares during the period. Envestnet Asset Management Inc. lifted its stake in LeMaitre Vascular by 9.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock worth $23,921,000 after purchasing an additional 25,680 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in LeMaitre Vascular by 0.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after acquiring an additional 1,680 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of LeMaitre Vascular by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier's stock valued at $18,037,000 after purchasing an additional 4,241 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Trading Down 0.6%

Shares of LMAT stock opened at $82.10 on Friday. The firm has a 50-day moving average price of $82.83 and a 200 day moving average price of $87.86. The company has a quick ratio of 13.83, a current ratio of 16.49 and a debt-to-equity ratio of 0.48. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a market capitalization of $1.85 billion, a P/E ratio of 41.46, a P/E/G ratio of 2.18 and a beta of 0.82.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The business had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. During the same quarter in the prior year, the company earned $0.44 EPS. LeMaitre Vascular's revenue was up 12.0% compared to the same quarter last year. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is 40.40%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 76,868 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer directly owned 1,796,783 shares in the company, valued at $154,146,013.57. This represents a 4.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have sold 100,000 shares of company stock valued at $8,556,857. Company insiders own 9.50% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.